DexCom, Inc. (NASDAQ:DXCM) – Analysts at Northcoast Research lifted their FY2017 earnings per share estimates for shares of DexCom in a note issued to investors on Thursday. Northcoast Research analyst E. Snyder now forecasts that the medical device company will post earnings of ($0.63) per share for the year, up from their previous estimate of ($0.70). Northcoast Research also issued estimates for DexCom’s Q4 2017 earnings at $0.06 EPS, Q1 2018 earnings at ($0.18) EPS, Q2 2018 earnings at ($0.01) EPS, Q3 2018 earnings at $0.08 EPS, Q4 2018 earnings at $0.17 EPS and FY2018 earnings at $0.06 EPS.

COPYRIGHT VIOLATION WARNING: This article was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2017/11/08/northcoast-research-equities-analysts-boost-earnings-estimates-for-dexcom-inc-dxcm.html.

Other equities research analysts also recently issued reports about the stock. Piper Jaffray Companies reissued a “buy” rating and set a $78.00 price target on shares of DexCom in a research note on Wednesday, July 12th. Wedbush restated an “outperform” rating and set a $76.00 price objective (down previously from $85.00) on shares of DexCom in a report on Thursday, September 28th. Oppenheimer Holdings, Inc. set a $92.00 price objective on shares of DexCom and gave the company a “buy” rating in a report on Wednesday, August 2nd. BMO Capital Markets restated an “outperform” rating and set a $62.00 price objective (down previously from $90.00) on shares of DexCom in a report on Thursday, September 28th. Finally, Northland Securities cut shares of DexCom from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $85.00 to $60.00 in a report on Thursday, September 28th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $70.69.

Shares of DexCom (NASDAQ DXCM) opened at $50.11 on Monday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86. DexCom has a 12 month low of $42.62 and a 12 month high of $88.80.

In related news, EVP Andrew K. Balo sold 3,244 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $71.18, for a total value of $230,907.92. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Richard Doubleday sold 1,635 shares of the company’s stock in a transaction dated Monday, October 23rd. The shares were sold at an average price of $44.82, for a total transaction of $73,280.70. Following the completion of the transaction, the executive vice president now owns 65,049 shares in the company, valued at $2,915,496.18. The disclosure for this sale can be found here. Insiders sold 23,208 shares of company stock worth $1,597,567 over the last 90 days. 1.70% of the stock is currently owned by corporate insiders.

Institutional investors have recently made changes to their positions in the business. Winslow Capital Management LLC acquired a new stake in DexCom during the second quarter worth about $117,451,000. BNP Paribas Arbitrage SA boosted its stake in shares of DexCom by 111.6% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,471 shares of the medical device company’s stock valued at $693,000 after purchasing an additional 4,995 shares in the last quarter. State Street Corp raised its holdings in DexCom by 2.5% in the 2nd quarter. State Street Corp now owns 1,549,843 shares of the medical device company’s stock valued at $113,374,000 after buying an additional 37,581 shares during the last quarter. Peregrine Capital Management LLC raised its holdings in DexCom by 24.5% in the 3rd quarter. Peregrine Capital Management LLC now owns 395,455 shares of the medical device company’s stock valued at $19,348,000 after buying an additional 77,868 shares during the last quarter. Finally, Macquarie Group Ltd. raised its holdings in DexCom by 67.2% during the 2nd quarter. Macquarie Group Ltd. now owns 242,598 shares of the medical device company’s stock worth $17,746,000 after purchasing an additional 97,479 shares during the last quarter.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.